VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma

Peter Preis, W. Scheithauer, E. Fritz, C. Zielinski, I. Kuehrer, A. Cortelezzi, E. Polli, L. Raldini, R. Pirker, A. Kriegisch, H. Ludwig

Research output: Contribution to journalArticlepeer-review

Abstract

Fifty-two previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon (rIFN) alpha-2 and chemotherapy or chemotherapy alone. Patients were treated with vincristine, melphalan, cyclophosphamide and prednisolone every 4-6 weeks. In the combined treatment arm rIFN was administered concurrently with chemotherapy as well as during chemotherapy free intervals. The combined regimen effected 17/21 (80.9%) responses as compared to 19/27 (70.4%) responses in VMCP treated patients. Addition of rIFN to chemotherapy did not enhance hematologic toxicity. These findings suggest a somewhat higher rate of objective response in the VPMC + rIFN group, although a significant improvement in median survival by adding rIFN to conventional first line polychemotherapy in myeloma patients has not yet been achieved.

Original languageEnglish
Pages (from-to)27-29
Number of pages3
JournalOncology Research and Treatment
Volume12
Issue number1
DOIs
Publication statusPublished - 1989

Keywords

  • Combinations treatment
  • Interferon-alpha-2
  • Multiples Myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this